Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Maria del Mar Gutierrez, Mª Gracia Mateo, Noemí Corbacho, Francesc Vidal & Pere Domingo. (2019) Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism & Toxicology 15:10, pages 787-802.
Read now
Read now
Francesco Giorgino, Alfred Penfornis, Valeria Pechtner, Raffaella Gentilella & Antonella Corcos. (2018) Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Preference and Adherence 12, pages 707-719.
Read now
Read now
Articles from other publishers (26)
Qing Li, Xiaoyan Deng, Yan-Jun Xu & Lin Dong. (2023) Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. Journal of Medicinal Chemistry 66:17, pages 11593-11631.
Crossref
Crossref
Ya Zhang, Jifa Zhang, Jiaxing Wang, Hao Chen, Liang Ouyang & Yuxi Wang. (2022) Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives. European Journal of Medicinal Chemistry 243, pages 114668.
Crossref
Crossref
Martina Belli, Lucy Barone, Alfonso Bellia, Domenico Sergi, Dalgisio Lecis, Francesca Romana Prandi, Marialucia Milite, Chiara Galluccio, Saverio Muscoli, Francesco Romeo & Francesco Barillà. (2022) Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. International Journal of Molecular Sciences 23:23, pages 14598.
Crossref
Crossref
David A. Griffith, David J. Edmonds, Jean-Philippe Fortin, Amit S. Kalgutkar, J. Brent Kuzmiski, Paula M. Loria, Aditi R. Saxena, Scott W. Bagley, Clare Buckeridge, John M. Curto, David R. Derksen, João M. Dias, Matthew C. Griffor, Seungil Han, V. Margaret Jackson, Margaret S. Landis, Daniel Lettiere, Chris Limberakis, Yuhang Liu, Alan M. Mathiowetz, Jayesh C. PatelDavid W. Piotrowski, David A. Price, Roger B. Ruggeri & David A. Tess. (2022) A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. Journal of Medicinal Chemistry 65:12, pages 8208-8226.
Crossref
Crossref
Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles M. Atisso, Mark C. Lakshmanan, Reema Mody, Sohini Raha & Hertzel C. Gerstein. (2021) Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Edin Begic & Mirsada Causevic. (2021) Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function. Heart, Lung and Circulation 30:11, pages 1675-1680.
Crossref
Crossref
Seunghun P. Lee, Jenson Qi, Guozhang Xu, Matthew M. Rankin, James Littrell, June Zhi Xu, Ivona Bakaj & Alessandro Pocai. (2021) GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action. Frontiers in Endocrinology 12.
Crossref
Crossref
Yusman Manchanda, Stavroula Bitsi, Yoyel Kang, Ben Jones & Alejandra Tomas. (2021) Spatiotemporal control of GLP-1 receptor activity. Current Opinion in Endocrine and Metabolic Research 16, pages 19-27.
Crossref
Crossref
Hussain Abdrabalrasool Alturaifi, Nof Tarq Alzayyat, Majed Shuraya Mohammed Alshahrani, Mujtaba Matar M Alnakhli, Abdulrahman Almuataz W Ezzi, Amal Ghazi A Alattas, Njoud Ali M. Osaysi, Maiar Najeeb Hijazi, Rehab Mohammed Aldossari & Mohammed Masoud Al Salem. (2021) Role of Additional GLP-1 Receptor Agonist to Insulin Regimen in Type 1 Diabetes among Pediatric Age. International Journal Of Pharmaceutical Research And Allied Sciences 10:3, pages 141-146.
Crossref
Crossref
Khaled Mesfer S Alghamdi, Bakr Abdullah M Alqahtani, Abdullah Hussain O Alhazmi, Zeyad Adel A Alsaedi, Waleed Talal M Alsulaimani, Faisal Besheit H Almatrafi, Abdulrahman Mohammed A Alhumaid, Muhannad Ahmed Alzahrani, Anas Abdullah G Al Alyany & Saeed Oudah S Alasiri. (2021) GLP-1 Receptor Agonist Cardiovascular Protection among Type-2 Diabetes Patients: A Literature Review. Pharmacophore 12:5, pages 76-80.
Crossref
Crossref
Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou & Shihchen Kuo. (2020) Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Federica Ferrari, Antonio Moretti & Roberto Federico Villa. (2020) The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs. Pharmacological Research 160, pages 105018.
Crossref
Crossref
Xiaowei Xiong, Weihang Lu, Xuan Qin, Qingyu Luo & Weimin Zhou. (2020) Downregulation of the GLP-1/CREB/adiponectin pathway is partially responsible for diabetes-induced dysregulated vascular tone and VSMC dysfunction. Biomedicine & Pharmacotherapy 127, pages 110218.
Crossref
Crossref
Juergen Sandow. 2020. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
243
261
.
Juergen Sandow. 2020. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
1
19
.
Yasuo Terauchi, Asuka Ozaki, Xiahong Zhao, Cheryl Teoh, Dena Jaffe, Yuki Tajima & Yujin Shuto. (2019) Humanistic and economic burden of cardiovascular disease related comorbidities and hypoglycaemia among patients with type 2 diabetes in Japan. Diabetes Research and Clinical Practice 149, pages 115-125.
Crossref
Crossref
Silvano Paternoster & Marco Falasca. (2018) Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. Frontiers in Endocrinology 9.
Crossref
Crossref
Natalia Petersen, Thomas M. Frimurer, Marianne Terndrup Pedersen, Kristoffer L. Egerod, Nicolai J. Wewer Albrechtsen, Jens J. Holst, Anne Grapin-Botton, Kim B. Jensen & Thue W. Schwartz. (2018) Inhibiting RHOA Signaling in Mice Increases Glucose Tolerance and Numbers of Enteroendocrine and Other Secretory Cells in the Intestine. Gastroenterology 155:4, pages 1164-1176.e2.
Crossref
Crossref
Michael HeileKathleen WyneLiana K. BillingsAnthony CannonYehuda HandelsmanMichael Shannon. (2018) Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S42-S52.
Crossref
Crossref
Janet McGill. (2018) Introduction. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S3-S4.
Crossref
Crossref
Michael A. Nauck, Thomas Jon Jensen, Carina Rosenkilde, Salvatore Calanna & John B. Buse. (2018) Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care 41:8, pages 1663-1671.
Crossref
Crossref
Andreas Andersen, Asger Lund, Filip K. Knop & Tina Vilsbøll. (2018) Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology 14:7, pages 390-403.
Crossref
Crossref
Jamal El Ouazzani, Amine Ghalem, Ghizlane El Ouazzani, Nabila Ismaili & Noha El Ouafi. (2018) Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. Journal of the Saudi Heart Association 30:2, pages 113-121.
Crossref
Crossref
Niels B. Dalsgaard, Tina Vilsbøll & Filip K. Knop. (2017) Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons. Diabetes, Obesity and Metabolism 20:3, pages 508-519.
Crossref
Crossref
A. Jamieson & N. Finer. (2017) Can we reconcile ‘the obesity paradox’ with recent cardiovascular outcome trials in diabetes?. Clinical Obesity 7:5, pages 255-259.
Crossref
Crossref
Ting-Ting Zhou, Fei Ma, Xiao-Fan Shi, Xin Xu, Te Du, Xiao-Dan Guo, Gai-Hong Wang, Liang Yu, Vatcharin Rukachaisirikul, Li-Hong Hu, Jing Chen & Xu Shen. (2017) DMT efficiently inhibits hepatic gluconeogenesis by regulating the Gαq signaling pathway. Journal of Molecular Endocrinology 59:2, pages 151-169.
Crossref
Crossref